<p>Centessa Pharmaceuticals（納斯達克代碼：CNTA - 獲取免費報告）在週四發佈的研究報告中，Wells Fargo &amp; Company 的股票分析師將其目標價格從 30.00 美元上調至 35.00 美元，Benzinga 報道。該券商目前對該股票給予 “增持” 評級。Wells Fargo &amp; Company 的目標價格意味着該股票當前價格有 31.89% 的潛在上漲空間。</p>
<ul>
<li>關注這隻生物科技股票，它仍然具有巨大的潛在上漲空間</li>
</ul>
<p>其他幾位股票分析師也對 CNTA 發表了評論。Lifesci Capital 在 9 月 3 日的研究報告中將 Centessa Pharmaceuticals 的股票評級上調至 “強力買入”。Truist Financial 在 11 月 5 日的研究報告中對 Centessa Pharmaceuticals 的股票設定了 30.00 美元的目標價格。Guggenheim 在 10 月 6 日的報告中重申了 “買入” 評級，並設定了 28.00 美元的目標價格。Stephens 在 10 月 28 日的研究報告中開始覆蓋 Centessa Pharmaceuticals，給予 “增持” 評級，並設定了 35.00 美元的目標價格。最後，Oppenheimer 在 8 月 29 日的研究報告中開始覆蓋 Centessa Pharmaceuticals，給予 “跑贏大盤” 評級，並設定了 40.00 美元的目標價格。一位股票研究分析師給予該股票 “強力買入” 評級，十位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價格為 33.11 美元。</p>
<p><strong>獲取我們對 Centessa Pharmaceuticals 的最新股票分析</strong></p>
<h2>Centessa Pharmaceuticals 股票下跌 0.6%</h2>
<p>CNTA 的股票在週四的午盤交易中下跌 0.16 美元，報 26.54 美元。該公司的交易量為 829,726 股，而其平均交易量為 1,090,736 股。該股票的市值為 35.5 億美元，市盈率為-14.56，貝塔值為 1.56。該公司的 50 日移動平均價格為 22.73 美元，200 日移動平均價格為 17.35 美元。該公司的速動比率為 10.57，流動比率為 10.56，債務與股本比率為 0.36。Centessa Pharmaceuticals 的 52 周最低價為 9.60 美元，52 周最高價為 27.18 美元。</p>
<p>Centessa Pharmaceuticals（納斯達克代碼：CNTA - 獲取免費報告）最近在 11 月 5 日發佈了季度財報。該公司報告每股收益為-0.41 美元，低於分析師共識預期的-0.39 美元，差距為 0.02 美元。平均而言，股票研究分析師預測 Centessa Pharmaceuticals 在當前年度的每股收益為-1.6 美元。</p>
<h2>Centessa Pharmaceuticals 的內部買賣</h2>
<p>在其他新聞中，內部人士 Mario Alberto Accardi 在 9 月 16 日的交易中出售了 8,172 股公司的股票。該股票以平均價格 21.40 美元出售，總交易額為 174,880.80 美元。出售後，該內部人士直接持有 197,394 股公司的股票，價值為 4,224,231.60 美元。此次交易使其持股減少了 3.98%。該出售在向證券交易委員會提交的文件中披露，文件可在此鏈接查看。此外，首席技術官 Tia L. Bush 在 9 月 24 日的交易中出售了 35,000 股股票。該股票以平均價格 24.00 美元出售，總價值為 840,000.00 美元。交易完成後，首席技術官持有 121,503 股公司的股票，價值為 2,916,072 美元。此次交易使其持股減少了 22.36%。該出售的披露信息可在 SEC 文件中找到。在過去 90 天內，內部人士共出售了 145,964 股公司股票，價值為 3,169,861 美元。公司內部人士持有公司股票的 7.09%。</p>
<h2>機構資金流入和流出</h2>
<p>幾家對沖基金和其他機構投資者最近對該公司的持倉進行了調整。紐約梅隆銀行在第一季度收購了 Centessa Pharmaceuticals 的新股份，價值約為 147,000 美元。Cerity Partners LLC 在第一季度購買了 Centessa Pharmaceuticals 的新股份，價值 471,000 美元。Wildcat Capital Management LLC 在第一季度購買了 Centessa Pharmaceuticals 的新股份，價值 4,053,000 美元。Windmill Hill Asset Management Ltd 在第一季度收購了 Centessa Pharmaceuticals 的新股份，價值 1,696,000 美元。最後，XTX Topco Ltd 在第一季度將其在 Centessa Pharmaceuticals 的持股增加了 81.0%。XTX Topco Ltd 現在擁有 41,057 股公司的股票，價值 590,000 美元，此前在上個季度又購買了 18,377 股。目前 82.01% 的股票由機構投資者和對沖基金持有。</p>
<h2>Centessa Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Centessa Pharmaceuticals plc 是一家臨牀階段的製藥公司，致力於為患者發現、開發和提供藥物。其產品管線包括 SerpinPC，一種用於治療 A 型和 B 型血友病的活化蛋白 C 抑制劑；以及 ORX750，一種用於治療嗜睡症和其他睡眠障礙的口服 OX2R 激動劑。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Centessa Pharmaceuticals</li>
<li>股票分析師評級和加拿大分析師評級</li>
<li>AMD 到 300 美元看起來很容易——這是為什麼 500 美元可能是下一個</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>超過 50 億美元的回購：DraftKings、AppLovin 和 Altria 在告訴你什麼</li>
<li>精通紀律：克服交易中的情緒挑戰</li>
<li>4 只高收益房地產股票，適合投資者防禦性購買</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Centessa Pharmaceuticals 嗎？</h2>
<p>在你考慮 Centessa Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Centessa Pharmaceuticals 並不在名單上。</p>
<p>雖然 Centessa Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CNTA

<p>富國銀行（Wells Fargo & Company）將 Centessa Pharmaceuticals（納斯達克代碼：CNTA）的目標股價從 30.00 美元上調至 35.00 美元，給予該股票 “超配” 評級。這表明相較於當前價格，潛在上漲幅度為 31.89%。其他分析師對 CNTA 也持積極評級，普遍評級為 “適度買入”，平均目標價格為 33.11 美元。Centessa Pharmaceuticals 的股票目前交易價格為 26.54 美元，市值為 35.5 億美元</p>

<p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) had its target price boosted by stock analysts at Wells Fargo &amp; Company from $30.00 to $35.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has an &#34;overweight&#34; rating on the stock. Wells Fargo &amp; Company's price target would indicate a potential upside of 31.89% from the stock's current price.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals（納斯達克代碼：CNTA - 獲取免費報告）在週四發佈的研究報告中，Wells Fargo &amp; Company 的股票分析師將其目標價格從 30.00 美元上調至 35.00 美元，Benzinga 報道。該券商目前對該股票給予 “增持” 評級。Wells Fargo &amp; Company 的目標價格意味着該股票當前價格有 31.89% 的潛在上漲空間。</p>
</div><ul>
<li>Wake Up to This Biotech Stock That Still Has Big Potential Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>關注這隻生物科技股票，它仍然具有巨大的潛在上漲空間</li>
</ul>
</div><p>Several other equities analysts have also commented on CNTA. Lifesci Capital upgraded shares of Centessa Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Wednesday, September 3rd. Truist Financial set a $30.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, November 5th. Guggenheim reaffirmed a &#34;buy&#34; rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Monday, October 6th. Stephens assumed coverage on Centessa Pharmaceuticals in a research report on Tuesday, October 28th. They set an &#34;overweight&#34; rating and a $35.00 price objective for the company. Finally, Oppenheimer started coverage on Centessa Pharmaceuticals in a research report on Friday, August 29th. They issued an &#34;outperform&#34; rating and a $40.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $33.11.</p>
<div class="lb-trans"><p>其他幾位股票分析師也對 CNTA 發表了評論。Lifesci Capital 在 9 月 3 日的研究報告中將 Centessa Pharmaceuticals 的股票評級上調至 “強力買入”。Truist Financial 在 11 月 5 日的研究報告中對 Centessa Pharmaceuticals 的股票設定了 30.00 美元的目標價格。Guggenheim 在 10 月 6 日的報告中重申了 “買入” 評級，並設定了 28.00 美元的目標價格。Stephens 在 10 月 28 日的研究報告中開始覆蓋 Centessa Pharmaceuticals，給予 “增持” 評級，並設定了 35.00 美元的目標價格。最後，Oppenheimer 在 8 月 29 日的研究報告中開始覆蓋 Centessa Pharmaceuticals，給予 “跑贏大盤” 評級，並設定了 40.00 美元的目標價格。一位股票研究分析師給予該股票 “強力買入” 評級，十位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價格為 33.11 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Centessa Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Centessa Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Centessa Pharmaceuticals Stock Down 0.6%</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 股票下跌 0.6%</h2>
</div><p>Shares of CNTA traded down $0.16 during midday trading on Thursday, hitting $26.54. The company had a trading volume of 829,726 shares, compared to its average volume of 1,090,736. The stock has a market cap of $3.55 billion, a price-to-earnings ratio of -14.56 and a beta of 1.56. The company's 50 day moving average price is $22.73 and its 200 day moving average price is $17.35. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a 52 week low of $9.60 and a 52 week high of $27.18.</p>
<div class="lb-trans"><p>CNTA 的股票在週四的午盤交易中下跌 0.16 美元，報 26.54 美元。該公司的交易量為 829,726 股，而其平均交易量為 1,090,736 股。該股票的市值為 35.5 億美元，市盈率為-14.56，貝塔值為 1.56。該公司的 50 日移動平均價格為 22.73 美元，200 日移動平均價格為 17.35 美元。該公司的速動比率為 10.57，流動比率為 10.56，債務與股本比率為 0.36。Centessa Pharmaceuticals 的 52 周最低價為 9.60 美元，52 周最高價為 27.18 美元。</p>
</div><p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02). On average, equities research analysts predict that Centessa Pharmaceuticals will post -1.6 EPS for the current year.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals（納斯達克代碼：CNTA - 獲取免費報告）最近在 11 月 5 日發佈了季度財報。該公司報告每股收益為-0.41 美元，低於分析師共識預期的-0.39 美元，差距為 0.02 美元。平均而言，股票研究分析師預測 Centessa Pharmaceuticals 在當前年度的每股收益為-1.6 美元。</p>
</div><h2>Insider Buying and Selling at Centessa Pharmaceuticals</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 的內部買賣</h2>
</div><p>In other news, insider Mario Alberto Accardi sold 8,172 shares of the business's stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $21.40, for a total transaction of $174,880.80. Following the sale, the insider directly owned 197,394 shares of the company's stock, valued at $4,224,231.60. The trade was a 3.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, CTO Tia L. Bush sold 35,000 shares of the stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $24.00, for a total value of $840,000.00. Following the completion of the transaction, the chief technology officer owned 121,503 shares of the company's stock, valued at $2,916,072. This trade represents a 22.36% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 145,964 shares of company stock valued at $3,169,861. Corporate insiders own 7.09% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 Mario Alberto Accardi 在 9 月 16 日的交易中出售了 8,172 股公司的股票。該股票以平均價格 21.40 美元出售，總交易額為 174,880.80 美元。出售後，該內部人士直接持有 197,394 股公司的股票，價值為 4,224,231.60 美元。此次交易使其持股減少了 3.98%。該出售在向證券交易委員會提交的文件中披露，文件可在此鏈接查看。此外，首席技術官 Tia L. Bush 在 9 月 24 日的交易中出售了 35,000 股股票。該股票以平均價格 24.00 美元出售，總價值為 840,000.00 美元。交易完成後，首席技術官持有 121,503 股公司的股票，價值為 2,916,072 美元。此次交易使其持股減少了 22.36%。該出售的披露信息可在 SEC 文件中找到。在過去 90 天內，內部人士共出售了 145,964 股公司股票，價值為 3,169,861 美元。公司內部人士持有公司股票的 7.09%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp acquired a new stake in shares of Centessa Pharmaceuticals during the first quarter valued at approximately $147,000. Cerity Partners LLC purchased a new stake in shares of Centessa Pharmaceuticals in the first quarter valued at $471,000. Wildcat Capital Management LLC purchased a new stake in shares of Centessa Pharmaceuticals in the first quarter valued at $4,053,000. Windmill Hill Asset Management Ltd acquired a new stake in shares of Centessa Pharmaceuticals in the first quarter worth $1,696,000. Finally, XTX Topco Ltd grew its holdings in shares of Centessa Pharmaceuticals by 81.0% during the first quarter. XTX Topco Ltd now owns 41,057 shares of the company's stock valued at $590,000 after buying an additional 18,377 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近對該公司的持倉進行了調整。紐約梅隆銀行在第一季度收購了 Centessa Pharmaceuticals 的新股份，價值約為 147,000 美元。Cerity Partners LLC 在第一季度購買了 Centessa Pharmaceuticals 的新股份，價值 471,000 美元。Wildcat Capital Management LLC 在第一季度購買了 Centessa Pharmaceuticals 的新股份，價值 4,053,000 美元。Windmill Hill Asset Management Ltd 在第一季度收購了 Centessa Pharmaceuticals 的新股份，價值 1,696,000 美元。最後，XTX Topco Ltd 在第一季度將其在 Centessa Pharmaceuticals 的持股增加了 81.0%。XTX Topco Ltd 現在擁有 41,057 股公司的股票，價值 590,000 美元，此前在上個季度又購買了 18,377 股。目前 82.01% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Centessa Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals plc 是一家臨牀階段的製藥公司，致力於為患者發現、開發和提供藥物。其產品管線包括 SerpinPC，一種用於治療 A 型和 B 型血友病的活化蛋白 C 抑制劑；以及 ORX750，一種用於治療嗜睡症和其他睡眠障礙的口服 OX2R 激動劑。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Centessa Pharmaceuticals</li>
<li>Stock Analyst Ratings and Canadian Analyst Ratings</li>
<li>AMD to $300 Looks Easy—Here’s Why $500 Could Be Next</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>$5B+ in Buybacks: What DraftKings, AppLovin, and Altria Are Telling You</li>
<li>Mastering Discipline: Overcoming Emotional Challenges In Trading</li>
<li>4 High-Yield Real Estate Stocks to Buy as Investors Get Defensive</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Centessa Pharmaceuticals</li>
<li>股票分析師評級和加拿大分析師評級</li>
<li>AMD 到 300 美元看起來很容易——這是為什麼 500 美元可能是下一個</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>超過 50 億美元的回購：DraftKings、AppLovin 和 Altria 在告訴你什麼</li>
<li>精通紀律：克服交易中的情緒挑戰</li>
<li>4 只高收益房地產股票，適合投資者防禦性購買</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=CNTA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Centessa Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Centessa Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Centessa Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Centessa Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Centessa Pharmaceuticals 並不在名單上。</p>
</div><p>While Centessa Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Centessa Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

富國銀行的分析師表示，Centessa Pharmaceuticals（納斯達克股票代碼：CNTA）的股價預計將會上漲